Clinical Trials
32 trialsTNT Esophagus
Duke University
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
MEND-IT II
Catharina Ziekenhuis Eindhoven
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
CROCOBIL
UNICANCER
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
City of Hope Medical Center
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
FOXHIPECT4
Maimónides Biomedical Research Institute of Córdoba
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
LEFT-PANC
Helsinki University Central Hospital
NACRE-2
UNICANCER
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
Seoul National University Bundang Hospital
PANORAMIX
GERCOR - Multidisciplinary Oncology Cooperative Group
FIRE-11
Charite University, Berlin, Germany
Pre-Operative Treatment in REseCTable COlon CanceR
Charite University, Berlin, Germany
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Harbin Medical University
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Sun Yat-sen University
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Xijing Hospital of Digestive Diseases
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
FD-IMPACT
Fudan University
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
Fudan University
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
Changhai Hospital
AFFORD
Sun Yat-sen University
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Ludwig-Maximilians - University of Munich